Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology

26-09-2023 | Brentuximab vedotin | Review Article

Role of brentuximab vedotin plus sirolimus in the treatment of classical Hodgkin lymphoma type post-transplant lymphoproliferative disorder: a case-based review

Authors: Kuangguo Zhou, Duanhao Gong, Yunfeng Han, Wei Huang

Published in: Annals of Hematology

Login to get access

Abstract

Post-transplant lymphoproliferative disorder (PTLD) is a common secondary malignancy after transplantation, which has been recognized as a life-threatening complication. Hodgkin lymphoma (HL)-type PTLD is the rarest of four subtypes of PTLD, which has no treatment guideline due to its rarity. HL-type PTLD includes classical HL-type PTLD (cHL-PTLD) and HL-like PTLD. In our study, we reported the case of successful treatment using brentuximab vedotin (BV) plus sirolimus for a patient with classical HL-type PTLD in detail. Lymph node biopsy showed a picture of classical HL with mixed cellularity subtype, and immunophenotyping suggested CD30 strong positivity. Due to his impaired physical condition, we decided against intensive chemotherapy and started BV treatment with immunosuppressive agents switched to sirolimus. The 66-year-old patient with cHL-PTLD had achieved a durable complete remission for over a 1-year follow-up period. Additionally, we analyzed the clinical profile and outcomes in PTLD patients who used BV monotherapy or combined therapy by literature review. In summary, this case-based review might provide clues that treatment of cHL-PTLD with new modalities such as BV monotherapy or combination therapy, together with improvements in the immunosuppressive regimens like sirolimus, might be a feasible and chemotherapy-free approach, but warrants further evaluation in a larger patient cohort.
Literature
1.
Dierickx D, Habermann TM (2018) Post-transplantation lymphoproliferative disorders in adults. New Eng J Med 378(6):549–562CrossRefPubMed
2.
Chan TS, Hwang YY, Gill H, Au WY, Leung AY, Tse E, Chim CS, Loong F, Kwong YL (2012) Post-transplant lymphoproliferative diseases in Asian solid organ transplant recipients: late onset and favorable response to treatment. Clin Trans 26(5):679–683CrossRef
3.
Choi SM, O’Malley DP (2018) Diagnostically relevant updates to the 2017 WHO classification of lymphoid neoplasms. Ann Diagn Pathol 37:67–74CrossRefPubMed
4.
Rosenberg AS, Klein AK, Ruthazer R, Evens AM (2016) Hodgkin lymphoma post-transplant lymphoproliferative disorder: a comparative analysis of clinical characteristics, prognosis, and survival. Amer J Hematol 91(6):560–565CrossRef
5.
André MPE, Carde P, Viviani S, Bellei M, Fortpied C, Hutchings M, Gianni AM, Brice P, Casasnovas O, Gobbi PG, Zinzani PL, Dupuis J, Iannitto E, Rambaldi A, Brière J, Clément-Filliatre L, Heczko M, Valagussa P, Douxfils J, Depaus J, Federico M, Mounier N (2020) Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: a pooled analysis of four randomized trials. Cancer Med 9(18):6565–6575CrossRefPubMedPubMedCentral
6.
Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illes A, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J, Grp EC-S (2018) Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. New Eng J Med 378(4):331–344CrossRefPubMed
7.
Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Cli Oncol 30(18):2183–2189CrossRef
8.
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. New Eng J Med 372(4):311–319CrossRefPubMed
9.
Adams H, Campidelli C, Dirnhofer S, Pileri SA, Tzankov A (2009) Clinical, phenotypic and genetic similarities and disparities between post-transplant and classical Hodgkin lymphomas with respect to therapeutic targets. Expert Opin Ther Targets 13(10):1137–1145CrossRefPubMed
10.
Li C, Romero-Masters JC, Huebner S, Ohashi M, Hayes M, Bristol JA, Nelson SE, Eichelberg MR, Van Sciver N, Ranheim EA, Scott RS, Johannsen EC, Kenney SC (2020) EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice. PLoS Pathog 16(6):e1008590CrossRefPubMedPubMedCentral
11.
Ranganathan S, Jaffe R (2004) Is there a difference between Hodgkin’s disease and a Hodgkin’s-like post-transplant lymphoproliferative disorder, and why should that be of any interest? Pediatr Trans 8(1):6–8CrossRef
12.
Kinch A, Amini RM, Hollander P, Molin D, Sundström C, Enblad G (2020) CD30 expression and survival in posttransplant lymphoproliferative disorders. Acta Oncol 59(6):673–680CrossRefPubMed
13.
Hong J, Johnson WT, Kartan S, Gonsalves AS, Fenkel JM, Gong JZ, Porcu P (2021) Durable response to brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (BV-CHP) in a patient with CD30-positive PTCL arising as a post-transplant lymphoproliferative disorder (PTLD). Current oncology (Toronto, Ont) 28(6):5067–5072CrossRefPubMed
14.
Mika T, Strate K, Ladigan S, Aigner C, Schlegel U, Tischoff I, Tischer-Zimmermann S, Eiz-Vesper B, Maecker-Kolhoff B, Schroers R (2019) Refractory Epstein-Barr Virus (EBV)-related post-transplant lymphoproliferative disease: cure by combined brentuximab vedotin and allogeneic EBV-specific T-lymphocytes. Front Med 6:295CrossRef
15.
Zinke-Cerwenka W, Troppan K, Beham-Schmid C, Pucher F, Linkesch W, Neumeister P (2013) Brentuximab vedotin is an effective treatment of classical hodgkin lymphoma type post-transplant lymphoproliferative disorder (ptld). Haematologica 98:572–572
16.
Canueto J, Ocio EM, Roman-Curto C (2018) Aggressive primary cutaneous CD30+lymphoproliferative disorder in an organ transplant recipient in sustained complete remission with brentuximab vedotin. Int J Dermatol 57(12):E153–E155CrossRefPubMed
17.
Gunes AK, Demir I, Pehlivan M (2021) Classical Hodgkin lymphoma-like post-transplant lymphoproliferative disease after allogeneic stem cell transplantation for primary myelofibrosis is successfully treated with nivolumab: a case report. J Oncol Pharm Pract 27(2):509–512CrossRefPubMed
18.
Hill BT, Tubbs RR, Smith MR (2015) Complete remission of CD30-positive diffuse large B-cell lymphoma in a patient with post-transplant lymphoproliferative disorder and end-stage renal disease treated with single-agent brentuximab vedotin. Leuk lymphoma 56(5):1552–1553CrossRefPubMed
19.
Pearse WB, Petrich AM, Gordon LI, Karmali R, Winter JN, Ma S, Kaplan JB, Behdad A, Klein A, Jovanovic B, Helenowski I, Smith SM, Evens AM, Pro B (2021) A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas. Leuk lymphoma 62(14):3493–3500CrossRefPubMed
20.
Choi M, Fink S, Prasad V, Anagnostopoulos I, Reinke P, Schmitt CA (2016) T cell PTLD successfully treated with single-agent brentuximab vedotin first-line therapy. Transplantation 100(3):E8–E10CrossRefPubMed
21.
Aguirre LE, Guzman ME, Lopes G, Hurley J (2019) Immune checkpoint inhibitors and the risk of allograft rejection: a comprehensive analysis on an emerging issue. Oncologist 24(3):394–401CrossRefPubMed
22.
Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemeister FB, Falchook GS, Karp DD, Wheler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale MA (2020) Safety and efficacy of vorinostat plus sirolimus or everolimus in patients with relapsed refractory Hodgkin lymphoma. Clin Cancer Res 26(21):5579–5587CrossRefPubMed
23.
Pape L, Ahlenstiel T (2014) mTOR inhibitors in pediatric kidney transplantation. Pediatr Nephrol 29(7):1119–1129CrossRefPubMed
24.
Naik MG, Arns W, Budde K, Diekmann F, Eitner F, Gwinner W, Heyne N, Jürgensen JS, Morath C, Riester U, Heller KM, Fischereder M (2021) Sirolimus in renal transplant recipients with malignancies in Germany. Clin Kidney J 14(9):2047–2058CrossRefPubMed
25.
Tedesco-Silva H, Del Carmen Rial M, Cruz Santiago J, Mazzali M, Pacheco-Silva A, Torres R (2019) Optimizing the clinical utility of sirolimus-based immunosuppression for kidney transplantation. Clin Trans 33(2):e13464CrossRef
Metadata
Title
Role of brentuximab vedotin plus sirolimus in the treatment of classical Hodgkin lymphoma type post-transplant lymphoproliferative disorder: a case-based review
Authors
Kuangguo Zhou
Duanhao Gong
Yunfeng Han
Wei Huang
Publication date
26-09-2023
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-023-05446-5
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits